• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareHealthcare Providers & ServicesNatera
    Picture of Natera logo

    NTRA — Natera News Story

    $404.790.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    • Market Cap
      $58.35bn
    • Enterprise Value
      $57.34bn
    • Revenue
      $2.31bn
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • NTRA Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    NTRA Dividends
    All News

    Brief: Natera Q4 Net Income USD -53.8 Million

    Picture of Natera logoNatera
    27/02/2025 21:05
    Feb 27 (Reuters) - Natera Q4 operating expenses USD 364.4 million.
    
    Q4 income from operations USD -64.7 million
    
    outlook FY gross margin 60-64%
    

    Recent news on Natera

    See all news
    • Brief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay

      09/10/2026 13:12
    • Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer

      05/10/2026 13:05
    • US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy

      25/09/2026 07:58
    • Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027

      22/09/2026 13:57
    • Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers

      12/08/2026 13:05

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.